Loading stock data…
$0.22-0.01 (-3.06%)
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel.
Enlivex Ltd. in the Healthcare sector is trading at $0.22 with a market capitalization of $205M. Wall Street consensus targets $80.00 (1 analysts), implying a +36834.4% move over the next 12 months. The stock is currently near its 52-week low of $0.21, remaining 97.7% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. Risk note: RSI 5 is oversold, raising the odds of a near-term bounce. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.86M↓ | -$2.56M↑ | -$3.08M↑ | -$3.50M↑ | -$4.88M |
| Net Income | $1.24B↑ | -$2.21M↓ | -$1.87M↑ | -$3.45M↑ | -$5.18M |
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM int...